Varicose Vein Treatment Devices – Market Insights – Europe

Although the COVID-19 global pandemic has negatively impacted the European varicose vein treatment device market in the short term, the market has largely recovered and will grow moderately over the remainder of the forecast period, supported by a shift toward and a changing reimbursement landscape for endovenous ablation technologies, namely ERFA and ELA, which will compete with surgical stripping procedures.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for varicose vein treatment devices in Europe from 2019 through 2031.

The COVID-19 pandemic has had a negative impact on the European varicose vein treatment device market.

To what extent were varicose vein treatment procedures postponed in Europe?

How fast will procedures recover in the short term?

Endovenous ablation varicose vein treatment options are becoming increasingly accessible in Europe.

What is the current reimbursement situation for ELA and ERFA procedures?

How will the recently approved MOCA and cyanoacrylate adhesive devices drive adoption?

What will be the impact of newly introduced noninvasive technologies, such as HIFU, on the varicose vein market in Europe?

How strongly will HIFU technology be adopted?

How will the availability of noninvasive technology, such as HIFU, change the market dynamics for other procedures in the market?

Sclerotherapy use will expand through 2031.

How will the introduction of polidocanol microfoam affect the market?

Surgical stripping continues to be commonly used in the treatment of varicose veins in some countries.

Why do these invasive procedures continue to be popular in some countries?

How will the increasing availability of minimally invasive treatment options impact surgical vein stripping procedure volumes?

Table of contents